Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - Successful Meeting with FDA on Phase III Design in NSCLC (ASX:IMM)

-- Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA® (pembrolizumab), MSD...read more

Immutep - Regulatory Clearance received for Phase 1 trial of IMP761 (ASX:IMM)

Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA – 17 July 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or &ldq...read more

Immutep - Positive results in TACTI-003 for 1L HNSCC cohort B patients (ASX:IMM)

Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatmen...read more

Immutep - Webcast to discuss data presented at ESMO Plenary Session (ASX:IMM)

To view the presentation, download the attached PDF.

INOVIQ - Successful completion of Share Purchase Plan (ASX:IIQ)

Highlights: -- IIQ successfully completed its share purchase plan with applications totalling A$7.293 million, exceeding its initial target of A$2 million. -- Directors exercised discretion...read more

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results (ASX:IMM)

SYDNEY, AUSTRALIA – July 3rd, 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...read more

Immutep - Webcast slides for new Efti clinical data in 1st line HNSCC (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - Positive topline results from ph2b in head & neck cancer (ASX:IMM)

Efti in combination with KEYTRUDA® (pembrolizumab) in first line head and neck squamous cell carcinoma (1L HNSCC) led to overall response rates that exceed KEYTRUDA monotherapy a...read more

Immutep signs agreement for anti-LAG-3 small molecules (ASX:IMM)

SYDNEY, AUSTRALIA – 25 June 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel L...read more

Immutep completes underwritten retail entitlement offer (ASX:IMM)

Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or the Company) is pleased to announce the completion of the retail component of its fully underwritten Entitlement Offer (details of which were a...read more

IVE Group Reaffirms FY24 Guidance (ASX:IGL)

IVE Group intended updating investors on its FY24 YTD performance at the recent Bell Potter Emerging Leaders Conference, however, due to the passing of the Group’s then Executive Chairman, Geo...read more

INOVIQ lodges SPP and Options Prospectus (ASX:IIQ)

INOVIQ Limited (ASX: IIQ) (INOVIQ or the Company) is pleased to announce that it has successfully completed the issue of 13,500,000 placement shares to institutional and sophisticated investors toda...read more

INOVIQ - Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

INOVIQ isolates brain-derived exosomes in Alzheimer's (ASX:IIQ)

INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that its NEURO-NET™ technology can isolate brain-derived exosomes in Alzheimer’s Disease. NEURO-NET captures exosomes secrete...read more

INOVIQ completes $7m placement (ASX:IIQ)

Highlights: -- INOVIQ successfully completed a A$7 million placement to institutional and sophisticated investors1 at A$0.50 per share. -- INOVIQ Board and Management have participated in the...read more

Viewing: 1 - 15 of 200 Previous | Next